Miist

Miist Therapeutics is a clinical-stage company developing instant-acting inhaled therapies that deliver relief in approximately 30 seconds, addressing conditions such as migraine, pain, anxiety, insomnia, and nausea. Their technology uses inhaled microparticles that are rapidly absorbed through the lungs, bypassing the slow digestion of oral pills. Miist has raised $7M and is advancing its lead migraine program (MST-02) toward Phase 1/2 clinical trials, with a 10-patient study already demonstrating 92% symptom relief within 2 minutes.

‍